(window["webpackJsonp"]=window["webpackJsonp"]||[]).push([["chunk-bf88e970","chunk-2d0dacc7"],{"144f":function(t,e,i){"use strict";i("ec3d")},"617a":function(t,e,i){"use strict";i.r(e);var r=function(){var t=this,e=t._self._c;return e("div",{staticClass:"d2-page-cover"},[e("div",{staticClass:"d2-page-cover__logo"},[t._t("default")],2),e("p",{staticClass:"d2-page-cover__title"},[t._v("MDA "+t._s(t.$version))]),t._m(0),e("p",{staticClass:"d2-page-cover__build-time"},[t._v("FINAL BUILD TIME "+t._s(t.$buildTime))]),t._t("footer"),t._m(1)],2)},a=[function(){var t=this,e=t._self._c;return e("div",{staticClass:"intro-text"},[e("p",[t._v("We propose a deep learning framework (DLST-MDA) for identifying potential miRNA-drug associations (MDAs). Sequence and structural information of drugs are combined to leverage the intrinsic properties of miRNAs and drugs, rather than relying on interaction graphs. Experiments were performed on a manually constructed dataset and verified that DLST-MDA outperforms peers in drug-miRNA association prediction. In addition, case study results on antitumor drugs (paclitaxel, oxaliplatin, and docetaxel) are supported by published literature, highlighting the potential of the model for discovering novel MDAs.")])])},function(){var t=this,e=t._self._c;return e("a",{attrs:{target:"blank",href:"https://github.com/scxdhr020629/pre_rna_02"}},[e("img",{staticStyle:{position:"absolute",top:"0",right:"0",border:"0",width:"150px"},attrs:{src:i("6cae"),alt:"Fork me on GitHub"}})])}],s=(i("144f"),i("2877")),n={},o=Object(s["a"])(n,r,a,!1,null,"fc6608ee",null);e["default"]=o.exports},"6cae":function(t,e,i){t.exports=i.p+"static/img/darkblue@2x.6dc8e790.png"},ec3d:function(t,e,i){}}]);